XML 40 R30.htm IDEA: XBRL DOCUMENT v3.25.3
Sale of PerClot (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 28, 2021
May 31, 2023
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Gain from sale of non-financial assets     $ 3,500 $ 0 $ 3,500 $ 0  
Revenue     113,388 95,779 325,338 291,229  
Per Clot              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Consideration for sale of assets $ 41,000            
Proceeds from sale of assets   $ 18,800          
Gain from sale of non-financial assets     3,500   3,500   $ 14,300
Revenue     600 $ 1,000 2,400 $ 2,300  
Receivables     5,000   5,000    
Per Clot | Transfer Of Perclot Manufacturing Equipment              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Contingent consideration receivable 800            
Per Clot | SMI              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Contingent liability payment 4,500 $ 4,500          
Payable     $ 1,500   $ 1,500    
Per Clot | Upon Our Receipt of Premarket Approval              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Proceeds from sale of assets 18,800            
Per Clot | Artivion Inc. And Starch Medical Inc.              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Consideration for sale of assets 54,500            
Proceeds from sale of assets 25,000            
Per Clot | Artivion Inc. And Starch Medical Inc. | Baxter Achievement Of Worldwide Sales              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Contingent consideration receivable $ 10,000            
Contractual period 21 months            
Per Clot | SMI              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Consideration for sale of assets $ 13,500            
Proceeds from sale of assets 6,000            
Per Clot | SMI | Baxter Achievement Of Worldwide Sales              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Contingent consideration receivable $ 3,000